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ABSTRACT
Background: It is understood that chronic allograft
failure occurs as a result of alloimmune and non-
alloimmune injury. Dendritic cells (DC) are thought to be
crucial in regulating (allo)immune airway damage and
interactions with epithelial cells are likely. Studies in
human lung transplantation are limited, however, and the
available literature on DC is inconsistent. This study
focused on the ex vivo influence of primary bronchial
epithelial cells derived from lung allografts on DC
differentiation.
Methods: Epithelial cell conditioned media (ECCM) were
added to monocytes differentiating into DC under the
influence of interleukin-4 and granulocyte macrophage-
colony stimulating factor. The resultant cells were
compared with DC cultured without ECCM and with
monocyte-derived macrophages. Expression of typical DC
(eg, CD1a) and macrophage (eg, CD14) markers was
assessed by flow cytometry. Phenotypical assessments
were complemented by functional studies of mannose
receptor-mediated phagocytosis (FITC-dextran uptake)
and antigen-presenting capability (mixed lymphocyte
reactions).
Results: Cells exposed to ECCM expressed significantly
lower levels of CD1a than unexposed DC. CD14
expression and phagocytic function were increased.
ECCM cultured cells also expressed lower levels of T cell
co-stimulatory molecules, secreted an anti-inflammatory
cytokine profile and had significantly reduced antigen-
presenting capability.
Conclusion: Using phenotypic and functional
approaches, this study has shown that ECCM from lung
allografts drives the production of macrophage-like cells
from monocytes rather than DC. The data suggest that
epithelial cells may restrain airway DC and potential
alloimmunity. It is unclear whether the observed effect is
specifically seen in lung transplant recipients or is a
general property of bronchial epithelial cells. This may
reflect a homeostatic inter-relationship between airway
epithelial and DC populations relevant both to lung
allografts and the lung more generally.
Lung transplantation is an accepted treatment for
end stage lung disease in carefully selected patients,
but success is compromised by chronic allograft
dysfunction.
1 Episodes of acute rejection are con-
sistently identified as a key risk factor for chronic
allograft dysfunction in International Registry
data. This devastating complication is referred
to as chronic rejection, reflecting the current
understanding that chronic alloimmune damage
is a key mechanism.
1 Dendritic cells (DC) are the
professional antigen-presenting cells of the airway
that initiate and regulate immune responses,
2 and
DC are thought to be crucial in regulating
(allo)immune damage in man. Studies in human
lung transplantation are limited, however, and the
available literature is inconsistent.
Yousem et al showed increased numbers of DC
in chronically rejecting lung allografts,
3 and a
subsequent study by Leonard et al indicated that
DC co-expressing the co-stimulatory molecules
CD80 and CD86 were more frequent in allografts
with chronic rejection.
4 In contrast, a previous
study from our centre showed that there were
fewer CD1a-positive DC in lung allografts than in
normal lungs.
5
The airway epithelium is a recognised focus of
damage in chronic allograft dysfunction, but it is
also increasingly accepted that airway epithelial
cells may play a key part as effector cells through
the production of a wide range of inflammatory
and immunomodulatory cytokines and growth
factors.
6 Physiologically, airway DC are thought
to sample the airway lumen continuously for
potential pathogens by projecting dendrites
through the airway epithelium,
7 and this close
spatial arrangement emphasises the potential for
epithelial cells to interact with and modulate DC
function.
8 Regamey et al
9 have recently studied this
potential using conditioned media produced from
alveolar and epithelial cell lines. They showed that
epithelial cells—both constitutively and following
stimulation with pro-inflammatory cytokines such
as tumour necrosis factor a (TNFa)—drove the
production of DC from monocytes in an inter-
leukin (IL)-15-dependent manner. IL15 is a cyto-
kine that shares biological properties with IL2, and
recombinant IL15 has been shown to cause the
production of DC from monocytes. A potential
implication of this study is that, in lung trans-
plantation, airway epithelial cells may promote a
situation which is deleterious to the graft, with an
expanded population of DC capable of orchestrat-
ing alloimmune injury.
To our knowledge, there are no studies in
primary epithelial cell cultures from lung allografts
evaluating the potential for epithelial cells to
modulate the production of dendritic cells from
monocytes. In this study, recognising the lack of
specificity of phenotypic markers alone, we have
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a previously validated ex vivo DC culture system. Using a
coordinated and multi-parametric approach, we tested the
hypothesis that epithelial cell conditioned media can modulate
phenotypic and functional properties of DC.
METHODS
Transplant patient clinical data
Clinically stable lung allograft recipients free from chronic
allograft dysfunction were used to obtain primary epithelial
cells. Clinical details are shown in table 1.
Bronchoscopy and bronchial sampling
Our post-transplant patients undergo surveillance bronchoscopy
at 1 week, 1, 3, 6 and 12 months as well as further bronchoscopy
if indicated on clinical grounds. All patients underwent pulmon-
ary function testing and an assessment of clinical status was
made based on standardised criteria.
10 Bronchoscopy was
performed in accordance with international guidelines.
11
Bronchoalveolar lavage (BAL) fluid was obtained from either
the lingula or right middle lobe and sent for routine
microbiological testing. Bronchial brushings (n=4–6) were
obtained from subsegmental bronchi using a standard single-
sheathed nylon cytology brush (5 Fr; Wilson Cook, Limerick,
Ireland) and dispersed in 5 ml phosphate buffered saline (Sigma,
Poole, UK). Transbronchial specimens were taken from either
the right or left lower lobe and sent for histopathological
examination to exclude acute vascular rejection based on
standard ISHLT criteria.
12
Primary bronchial epithelial cell culture
Primary bronchial epithelial cells were obtained from bronchial
brushings as previously described.
13 In brief, endobronchial
brushings were plated in serum-free bronchial epithelial basal
media (BEBM; Cambrex, Wokingham, UK) supplemented with
single quouts and antibiotics. When 70–90% confluent, cells
were passaged using trypsin to T75 flasks or 24-well plates.
When 80–90% confluent, 24-well plates were rested for 24 h in
serum-free BEBM media. Epithelial cell conditioned super-
natants (ECCM) were then collected following 48 h of culture.
Microbiological contamination of ECCM was excluded by
testing for normal respiratory flora and fungal and bacterial
pathogens in an independent clinically-accredited laboratory.
Generation of DC and macrophages from monocytes
Monocytes were isolated from freshly drawn peripheral blood
from healthy donors or buffy coats, as described previously.
14
Briefly, peripheral blood mononuclear cells were isolated by
density centrifugation on Lymphoprep (Axis-Shield Diagnostics,
Dundee, UK). CD14+ monocytes were isolated by positive
magnetic selection using anti-CD14 magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Monocytes
were cultured at 0.5610
6 cells/ml for 6 days in 0.5 ml BEBM
and 0.5 ml RPMI-1640 supplemented with 10% fetal bovine
serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. To generate DC, IL4 and granulocyte-macro-
phage colony stimulating factor (GM-CSF) (50 ng/ml each,
Immunotools, Friesoythe, Germany) and to generate macro-
phages (Mph), macrophage colony stimulating factor (M-CSF)
(50 ng/ml, R&D Systems, Abingdon, UK) were added to the
monocyte cultures on days 0 and 3. After 6 days, cells were
stimulated with lipopolysaccharide (LPS, 100 ng/ml, Sigma) or
were left untreated. After 24 h the supernatants were harvested
and assayed for IL12p70 and IL10 by ELISA, and the DC and
MPh were extensively washed before performing functional
assays and flow cytometry.
Effect of ECCM on DC cultures
Monocytes were cultured under DC-generating conditions as
described above, but with 0.5 ml ECCM instead of BEBM. The
ECCM-modified DC cultures are referred to as antigen-
presenting cells (APC) throughout the paper.
Flow cytometry
The following antibodies were used for cell surface marker
analysis: CD1a (NA1/34; Dako, Glostrup, Denmark), CD14
(M5E2), CD68 (27–35), CD86 (2331 FUN-1), CD83 (Hb15e) and
HLA-DR (L243; all from BD Pharmingen, San Jose, California,
USA). Isotype-matched control antibodies were used to confirm
that staining was specific (data not shown). Cells were
centrifuged and resuspended in FACS buffer (phosphate
buffered saline supplemented with 3% FCS, 2 mM EDTA and
0.01% sodium azide). Human IgG (Grifols, Los Angeles,
California, USA) was added with antibodies to prevent Fc
receptor binding. To detect intracellular CD68, a permeabilisa-
tion step was included (Cytofix/cytoperm; BD Biosciences,
Oxford, UK). Cells were incubated on ice for 30 min, washed
and resuspended in FACS buffer. Data were collected on a
Becton Dickinson FACScan and analysed using FlowJo
(Treestar, Ashland, Oregon, USA).
Phagocytosis assay
Fluorescent-labelled dextran (FITC-dextran; Sigma) was used to
assess the mannose receptor (MR)-mediated phagocytic capa-
city of the cell types. Cells were incubated with FITC-dextran at
Table 1 Clinical details of patients from whom primary epithelial cell cultures were derived
Patient
sample
Time after
transplant
(months) Diagnosis Transplant
Age at time
of transplant
(years) Biopsy FEV1
BAL
microbiology BOS score
11 2 a1-antitrypsin deficiency: emphysema SL 50.3 A1 B0 1.82 Negative 0
2 6 Primary pulmonary hypertension HL 52.5 A0 B0 2.57 Negative 0
3 1 Idiopathic pulmonary fibrosis SL 57.4 A2 B1 1.34 Scanty E coli 0
4 12 Idiopathic pulmonary fibrosis SL 54.4 AX BX 3.87 Scanty P
aeruginosa
0
5 3 Emphysema SL 54.9 A1 B0 1.43 Negative 0
6 12 Primary pulmonary hypertension HL 52.5 A0 B0 2.70 Negative 0
7 6 Primary pulmonary hypertension HL 60.4 A2 B0 3.09 Negative 0
Biopsy, transbronchial biopsy scored as per international guidelines
12 for acute and chronic rejection.
BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans; FEV1, forced expiratory volume in 1 s; HL, heart lung; SL, single lung.
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extracellular binding of FITC-dextran. Cells were extensively
washed and intracellular FITC-dextran was quantified by flow
cytometry.
Mixed lymphocyte reaction (MLR)
1610
4 DC, APC or MPh were cultured with 1610
5 allogeneic
CD3+ T lymphocytes in 200 ml cultures in a 96-well plate.
Supernatants were harvested after 6 days and assayed for
interferon c (IFNc) by ELISA. Proliferation was assessed by
incorporation of
3H-thymidine for the last 8 h of culture by
scintillation counting (Microbeta TriLux, Perkin Elmer, USA).
Enzyme-linked immunosorbent assay (ELISA)
Cytokine levels in the supernatants were measured by specific
sandwich ELISA performed with commercially available
matched antibody pairs. The following cytokines were mea-
sured: IL8 and IL15 (R&D Systems), IFNc, IL6, IL10 and
IL12p70 (BD Pharmingen).
Statistical analysis
Statistical software used for the analysis was GraphPad Prism
Version 4. In the upper panels of fig 1 the medians of CD1a,
CD14 and CD68 expression were compared by the non-
parametric paired Wilcoxon test for the following comparator
group pairs: DC and APC; APC and MPh. In the lower panels of
fig 1 the medians of CD86, CD83 and HLA-DR expression were
compared by the non-parametric paired Wilcoxon test for the
following comparator group pairs: DC and LPS-DC; APC and
LPS-APC; MPh and LPS-MPh; LPS-DC and LPS-APC; LPS-APC
and LPS-MPh. In fig 2 the means of IL10 and IL12p70
production and the mean of dextran-FITC uptake were
compared by t test for the following comparator group pairs:
DC and APC; APC and MPh. Only significant results (p,0.05)
are indicated in the figures.
RESULTS
Bronchial ECCM favour differentiation of monocytes towards a
macrophage phenotype at the expense of DC
Table 2 summarises data showing that bronchial ECCM
contained a mixture of secreted cytokines including measurable
levels of IL8 and IL6. IL15 was not detectable in any of the
epithelial cell cultures.
Figure 1 shows the expression of markers by the three
monocyte-derived cell populations: (1) DC (generated with IL4
and GM-CSF); (2) APC (cultured by adding ECCM to the IL4/
GM-CSF DC cultures); and (3) MPh (generated with M-CSF).
The effect of a further 24 h stimulation with LPS was assessed
for the above cell populations. This is known to activate
immature DC, resulting in the upregulation of markers involved
in T cell activation.
Phenotypic markers assessed were the DC marker CD1a, the
MPh markers CD14 and CD68, the antigen presenting molecule
HLA-DR, the classical DC maturation marker CD83 and the T
cell co-stimulatory molecule CD86. The salient findings of these
experiments showed that ECCM drove the production of MPh-
like cells from monocytes. In the APC population there were
significantly fewer cells expressing the DC marker CD1a than in
the DC population, contrasting with significantly more cells
expressing the MPh marker CD14. APC also expressed higher
levels of CD68, but this was not statistically significant.
Figure 1 Phenotype of monocyte-derived cell populations. Expression of markers by dendritic cells (DC), antigen-presenting cells (APC) and
macrophages (MPh) was assessed by flow cytometry. Lower panels include cell populations activated with lipopolysaccharide (LPS) for 24 h. Debris
and dead cells were excluded on the basis of forward scatter and side scatter. Data shown for at least six independent experiments; different epithelial
cell donors and blood donors were used in each experiment. Horizontal lines represent median values. *p,0.05 (Wilcoxon test).
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significant upregulation of HLA-DR; CD83 and CD86 on both
DC and APC, but not MPh. However, the levels of CD83 and
CD86 were significantly lower on LPS-activated APC than on
LPS-activated DC, while expression levels of HLA-DR were
similar.
We also measured the production of the anti- and pro-
inflammatory cytokines IL10 and IL12p70, respectively, by DC,
APC and MPh that had been activated by LPS for 24 h (fig 2A).
APC produced significantly higher levels of IL10 and lower levels
of IL12p70 than DC, again resembling MPh rather than DC.
Non-stimulated cell populations did not secrete detectable levels
of cytokines (data not shown).
ECCM induce APC that functionally resemble MPh rather than
DC
Because the phenotype of APC resembled the phenotype of MPh
rather than DC, we hypothesised that the functional character-
istics of APC would also be more macrophage-like. To test this
hypothesis we assessed functional abilities that are typical for
either MPh (phagocytosis) or DC (T cell stimulation).
Figure 2B depicts an assay of mannose receptor (MR)-
mediated phagocyte function. Here the MPh represent a
positive control as professional phagocytes. Like MPh, ECCM-
induced APC exerted greater MR-mediated phagocytic activity
than DC.
Figure 3 summarises the results of mixed lymphocyte
reactions to assess the immunostimulatory capacity of the
monocyte-derived populations. Here LPS-activated DC repre-
sent a positive control as professional APC, potently initiating T
cell responses. Activation of DC with LPS resulted in enhance-
ment of T cell stimulatory activity of DC, with higher induction
of proliferation and production of the prototypic cytokine IFNc
by allogeneic T cells. This enhanced T cell stimulatory capacity
of LPS-DC is consistent with the higher expression of CD83 and
CD86 and the production of the Th1-inducing cytokine
IL12p70. In contrast, activation of APC with LPS did not
enhance their immunostimulatory capacity, and the induction
of IFNc production was greatly reduced compared with DC and
LPS-DC. MPh were the poorest stimulators of T cell prolifera-
tion and only induced very low levels of IFNc. These
experiments show that ECCM-induced APC have a low
immunostimulatory capacity compared with DC.
Together these data indicate that ECCM skew monocyte-
derived DC towards a macrophage-like population in terms of
phenotype and function.
DISCUSSION
This study has shown that conditioned media from lung
allograft primary bronchial epithelial cells drives the production
of macrophage-like cells from monocytes rather than DC.
Although there was biological variability, a broad range of
phenotypic and functional markers consistently supported this
finding. Our data suggest that epithelial cells from allograft
recipients promote production of MPh while restraining the
Figure 2 Cytokine production and
mannose receptor-mediated phagocytic
capacity of monocyte-derived cell
populations. (A) Cytokine production.
Dendritic cells (DC), antigen-presenting
cells (APC) and macrophages (MPh) were
activated for 24 h with lipopolysaccharide
(LPS, 100 ng/ml). Levels of interleukin
(IL)-10 and IL12p70 were determined by
specific sandwich ELISA. The mean
(SEM) production of six independent
experiments is shown. (B) Phagocytic
activity. Uptake of FITC-dextran by DC,
APC and MPh after 1 h was assessed by
flow cytometry. Data are shown as the
mean (SEM) of at least three independent
experiments. Different epithelial cell
donors and blood donors were used in
each experiment. *p,0.05 (t test).
Table 2 Summary of IL8 and IL6 measurements made from ECCM
Patient ECCM sample IL8 (pg/ml) IL6 (pg/ml)
1 551 31
2 2412 30
3 2809 204
4 340 Not detectable
5 923 84
6 3453 206
7 1472 250
ECCM, epithelial cell conditioned media; IL, interleukin.
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whether the observed effect is specifically seen in lung
transplant recipients or might be a general property of bronchial
epithelial cells. It remains to be studied whether this is relevant
both to lung allografts and to the lung more generally.
The biology of professional APCs in the airway is likely to be
of key importance in the alloimmune component of chronic
allograft dysfunction which is commonly referred to as chronic
rejection. There are few studies in lung transplantation,
however, and these are restricted to phenotypic approaches
using different markers which report conflicting data. Two
studies indicate that, in chronic rejection, there are increased
numbers of DC
34 with an earlier study from our group
indicating lower numbers of CD1a+ DC in lung allografts.
5
It is accepted that the local environment to which DC are
exposed is a key factor in their maturation and function.
8 The
close spatial relationship between airway epithelial cells and DC
indicate that epithelial cells might be an important influence.
8
Airway epithelial cells secrete a spectrum of proinflammatory
cytokines and growth factors which play an important role in
local defence and in the induction of a systemic inflammatory
response. In lung allograft primary cultures we have previously
reported that airway epithelial cells constitutively secrete GM-
CSF, M-CSF and IL6,
6 factors that increase the production and
mobilisationofmonocytesfrom thebonemarrowand influxinto
the lung. In ex vivo models where DC are produced from
monocytes GM-CSF is used in the conditioning protocols,
emphasising the potential for epithelial cell-derived products to
influence DC differentiation. Further research is required to
define the epithelial cell factor(s) interfering with DC differentia-
tion. We considered the possibility that the anti-inflammatory
cytokine IL10 was involved, but could not detect this cytokine in
ECCM by ELISA (lower limit of detection 15 pg/ml, data not
shown). Another possibility is IL6, which was detectable in the
majority of the ECCM used in this study. It has been reported
that high levels (.50 ng/ml) but not low levels of IL6 (20 pg/ml)
switch monocyte differentiation from dendritic cells to macro-
phages.
15 Because ECCM contain only moderate levels of IL6 (30–
250 pg/ml, table 2), we feel it is unlikely that IL6 by itself was
responsible for the observed inhibitory effects on DC differentia-
tion, although it cannot be excluded that IL6 synergised with
other soluble ECCM component(s).
The potential for epithelial cells to interact with DC was
recently studied by Regamey et al using lung A549 and airway
BEAS-2B epithelial cell lines.
9 Conditioned media from the
epithelial cells contained IL15 both constitutively and following
stimulation with inflammatory stimuli. Addition of these media
to monocytes led to an upregulation of IL15 receptor mRNA
expression, with differentiation of monocytes to functional
DC.
9 In the allograft setting, where upregulated alloimmunity is
damaging,
11 6 these findings are of potential significance, but
there are no previous data of which we are aware in primary
airway epithelial cells from allograft patients.
Our findings are not consistent with those of Regamey et al.
Using accepted markers for DC and macrophages we consis-
tently showed that conditioned media from allograft recipient
primary epithelial cells favoured the production of macrophage-
like cells from monocytes. Phenotypic markers were corrobo-
rated by functional phagocytic and immunostimulatory assays.
Our data showed that incubation of monocytes with patient-
derived ECCM consistently yielded a population of cells with
low expression of DC markers and poor T cell stimulatory
ability. In contrast, we observed significant expression of
macrophage markers and competent phagocyte function. The
conditioned media from allograft primary epithelial cells did not
contain detectable levels of IL15 as measured by ELISA (data not
shown), which may reflect differences between primary
epithelial cells and cell lines and/or differences in the experi-
mental set-up (eg, cell density).
A main difference between our work and the study by
Regamey et al was that we used primary epithelial cells sourced
from lung transplant recipients. It is of interest that a previous
study by Ohtoshi et al using upper airway epithelial cells from
polyps drove the production of MPh from monocytes, although
this was in atopic but otherwise healthy volunteers and not a
transplant-related study investigating DC markers.
17 More
recent work involving an airway epithelial cell line and murine
DC has also indicated that epithelial cells may modify immune
responses by inducing an ‘‘anti-inflammatory’’ DC-suppressing
microenvironment.
18 This may indicate that our data which as
far as we are aware, are the first in primary human cells, have
relevance beyond lung transplantation. Promoting the produc-
tion of MPh-like cells is arguably physiologically appropriate in
the human airway since MPh form an important defence in the
constantly exposed lungs. The antimicrobial activity of MPh is
promoted by efficient phagocytosis and, together with the
barrier function provided by the tight airway epithelium, MPh
represent a first line of innate immunity.
19
Figure 3 Immunostimulatory capacity of monocyte-derived cell populations. Dendritic cells (DC), antigen-presenting cells (APC) and macrophages
(MPh) were or were not activated with lipopolysaccharide (LPS) for 24 h and were used as stimulator cells in a mixed lymphocyte reaction with
allogeneic CD3+ T cells. After 6 days, T cell proliferation was determined by
3H-thymidine incorporation and interferon c (IFNc) production by specific
sandwich ELISA. Results are representative of three independent experiments and are shown as mean (SEM). Different epithelial cell donors and blood
donors were used in each experiment.
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allograft may be important in promoting alloimmunity.
16 The
emerging paradigm is that non-alloimmune damage due to
potentially occult challenges such as infection and aspiration
may combine with alloimmunity to yield damage.
16 The airway
epithelium is a target for injury, with damage and loss of barrier
function in chronic allograft dysfunction. Our recent finding of
decreased levels of the epithelial cell product secretory leukocyte
proteinase inhibitor (SLPI) in the BAL fluid of lung allograft
recipients with bronchiolitis obliterans supports this model.
20 In
addition, our study showed that the antimicrobial peptide LL-37
is elevated in the BAL fluid of allograft recipients with chronic
dysfunction.
20 As well as being an antimicrobial, LL-37 has been
shown to interact with DC, and CD86 expression following LL-
37 treatment has been shown to be increased in a dose-
dependent manner.
21
In the present study we showed that monocytes incubated
with ECCM and then stimulated with the Toll like receptor 4
agonist LPS upregulated HLA-DR, CD83 and CD86, which are
markers of DC activation. However, the T cell stimulatory
capacity of ECCM-induced APC was not enhanced. It is likely
that the high production of the anti-inflammatory cytokine
IL10 by LPS-activated APC will have counteracted the T cell co-
stimulatory activity of CD83 and CD86, but this requires
further investigation. Interestingly, the ECCM-induced APC
resemble regulatory DC (eg, high IL10 production, low T cell
stimulatory capacity) described previously by us and
others,
14 22 23 but whether they are capable of inducing T cell
tolerance requires further investigation.
Our data emphasise the need for primary cell data to be
assessed along with experiments involving cell lines, although
primary studies are themselves limited by technical difficulty
and the fact that they are resource intensive. Further studies
would be useful to investigate conditioned media sourced from
epithelial cells from subjects with chronic allograft dysfunction.
This was beyond the scope of this present study, since our
experience is that such cultures commonly fail due to antibiotic-
resistant patient-derived infection.
13 Such work may require
specialised protocols and augmented—possibly patient-speci-
fic—antibiotic approaches.
Our experiments were all performed using epithelial cells at
early passage (I–II) in cell cultures free from transplant
maintenance therapies. We do not expect previous patient
immunosuppression to be responsible for our findings, but
transplant medications might affect the interplay between
epithelial cells and DC in the airway. This could also be an
avenue for further research. An aim of this could be to elucidate
the most appropriate balance between appropriate immuno-
suppression and preservation of airway homeostasis, with
maintenance of epithelial function and appropriate networking
with airway DC representing a desirable goal.
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